As SGLT-2 inhibition does not appear to require preserved kidney function or overt hyperglycaemia to have important pharmacological effects, another large, prospective, placebo-controlled trial called EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin) is now planned in order to test definitively whether SGLT-2 inhibition with empagliflozin can reduce the risk of cardio-renal outcomes in a broad range of people with CKD, including individuals with overt albuminuria and those with low eGFR, irrespective of their level of albuminuria. This evidence concerns the gene SLC5A2 and Hyperglycemia.